Physician profile
Ronnie Blount
NPI 1720159098
$87,630.39
in general payments reported to CMS, 2019-2025
28 companies · $945 in 2025
The $945 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $229 · 2021: $437 · 2022: $668 · 2023: $340 · 2024: $85K · 2025: $945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $84K · Food and Beverage: $1,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $84,418.03 |
| Food and Beverage | $1,736.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $84,418.03 | 2024 | Neurostar Tms Therapy System |
| Lundbeck LLC | $517.83 | 2020-2025 | Rexulti |
| Abbvie INC. | $424.88 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $423.92 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $345.17 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $319.10 | 2019-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $210.23 | 2019-2025 | Uzedy |
| Idorsia Pharmaceuticals US INC | $129.14 | 2023-2025 | Quviviq, Quviviq |
| Alkermes, INC. | $128.55 | 2021-2024 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $104.45 | 2020-2025 | Ingrezza |
| Eisai INC. | $88.10 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $80.60 | 2022-2025 | Spravato, Invega Sustenna |
| Harmony Biosciences LLC | $71.41 | 2022 | |
| Sunovion Pharmaceuticals INC. | $57.20 | 2021-2022 | |
| Bausch Health US, LLC | $39.69 | 2023-2025 | Aplenzin, Wellbutrin |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $39.09 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $37.96 | 2025 | Cobenfy |
| Allergan, INC. | $30.73 | 2020 | |
| Vanda Pharmaceuticals INC. | $29.38 | 2025 | Fanapt |
| Tempus Ai, INC | $18.33 | 2024 | |
| Owp Pharmaceuticals, INC. | $18.31 | 2025 | Subvenite |
| Neos Therapeutics, Lp | $18.11 | 2025 | Exxua |
| Ironshore Pharmaceuticals INC. | $15.29 | 2019 | |
| Adlon Therapeutics L.P. | $13.71 | 2020 | |
| Merck Sharp & Dohme LLC | $13.53 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.91 | 2023 | Qelbree |
| Noven Therapeutics, LLC | $12.57 | 2020 | |
| Orexo US, INC. | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronnie Blount listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.